Savara Stock Price. Everything You Need To Know About The Savara Stock!
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 28 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), a inhaled biologic, is a granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
Savara Stock Price. Everything You Need To Know About The Savara Stock! performance
- Employees 28
- Company HQ Austin
- Website http://savarapharma.com/
- SVRA Asset Type Common Stock
- SVRA Market Capitalization 609.2M
- Earnings Per Share -0.33
- Dividends Per Share None
- Dividend Date 2017-04-28
- Quarterly Earnings Growth 0
Are you interested in investing in the stock market from Malaysia, Thailand, Indonesia, or Vietnam? Look no further than Savara. Savara is a promising stock that offers great investment opportunities for retail investors in these countries. As an investment platform, Zorion provides valuable insights and recommendations for investing in Savara to help you make informed decisions. With our educational resources, you can further enhance your investment knowledge and gain an edge in the market. Don’t miss out on the chance to invest in Savara and grow your wealth. Visit Zorion today to learn more about how you can invest in Savara from Malaysia, Thailand, Indonesia, and Vietnam.
